Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Ben Land-Maycock

Partner

London +44 20 7067 2135

  • About
  • Representative Matters
  • Credentials
  • About

    Ben Land-Maycock helps clients execute strategic transactions. He acts on a full scope of transactional matters including public and private mergers and acquisitions, venture capital and private equity investments, restructurings, and IPOs and equity capital markets transactions.

    Ben regularly advises companies in the technology, life sciences, and energy sectors. He represents many private equity and venture capital (including corporate venture capital) investors on their investments and exits.

    Ben also provides day-to-day company law advice for public and private companies.

    Areas of Expertise

  • Practices and Industries
  • Representative Matters

    Recent Mergers and Acquisitions

    • Ergomed plc on its £703m takeover by Permira Private Equity.
    • Regeneron on its acquisition of Oxular Limited, a UK retinal disease company.
    • Oxford Immunotec, a NASDAQ-listed UK plc, on its $591 million sale to PerkinElmer by UK scheme of arrangement.
    • MultiplAI Health on its $340m merger with OmnigenicsAI and APx Acquisition Corp. I, a publicly traded SPAC.
    • Main Market listed Oxford Biomedica on its acquisition of contract manufacturing and development business ABL Europe.
    • AstraZeneca on its $150 million acquisition of the US commercial rights of Turdoza and Duaklir from Circassia Pharmaceuticals.
    • Arecor Therapeutics plc on its acquisition of Tetris Pharma.
    • A Saudi Arabia based private equity group on its acquisition of renewable energy assets.
    • BB Energy on its acquisition of Solarcentury’s African solar power assets.
    • Merck on its €2.1 billion acquisition of Antelliq Group, a leader in digital animal identification, traceability and monitoring solutions.
    • A NYSE-listed high tech manufacturing group on its acquisition of a UK-headquartered global manufacturing and distribution business.
    • Ziylo Ltd and its selling shareholders on its sale to Novo Nordisk for a total consideration of up to $800 million.

    Recent Fundraisings and Investments

    • Draig Therapeutics Limited on its $140m Series A financing, one of the largest UK university spin-outs ever.
    • Portal Biotech Limited on its $35m Series A financing led by NATO.
    • National Grid Partners Limited on its Series B and Series C investments into Luminance, a legal AI platform.
    • CN Bio, an organ-on-a-chip technology company, on its $21m Series B financing.
    • Sanofi on its $60m investment into Gyroscope Therapeutics Holdings plc.
    • Pulmocide Limited on each of its $144 million Series C Financing and its $30 million Series B Financing.
    • QuantuMDx Group on its £15m fundraising from Vita Spring for development of its rapid PCR tests.
    • Novo Ventures, Cowen Healthcare Ventures, F-Prime and Sanofi as a syndicate on their £44.5 million Series B financing of NodThera Limited.
    • Revolo Bio Limited on its $53 million Series B financing.
    • RA Capital, SV Life Sciences, and Samsara BioCapital as a syndicate on their £25 million Series A-1 investment in Enara Bio Ltd.
    • National Grid Partners on its investments into Risilience, Audio Analytic Ltd and CNIGuard Ltd.
    • Tencent on its lead Series A investment into Everledger, a UK-based blockchain startup.
    • Takeda Ventures, Inc. on its investments into Transine Therapeutics Limited and Catamaran Bio, Inc.
    • Sofinnova Partners and Brandon Capital Partners on their seed financing of Myricx Pharma.
    • Astellas Ventures Management on its investments into NeoPhore Ltd and Phoremost Ltd.
    • Crescendo Biologics Limited on its $70 million Series B Financing.
    • GSK Equity Investments and Advent Life Sciences on their Series A investment into MiroBio Limited.
    • Syncona Limited on its founding investments in SwanBio Therapeutics Limited and Orbit Biomedical Limited.

    Other Recent Transactional Work

    • Advising Merck & Co., Inc. on its global reorganisation in connection with the spin-off of its women’s health, trusted legacy brands and biosimilars businesses.
    • Oxford Immunotec, a NASDAQ listed UK plc, on its $100 million share buyback program.
    • A diagnostics company focused on immune-regulated conditions in a $40 million follow-on offering.
    • A private equity fund in relation to a €45,000,000 credit facility.

    Areas of Expertise

  • Credentials
    Education
    • College of Law, New Zealand, 2013
        • Certificate in Professional Legal Studies
    • Victoria University of Wellington, LL.B., 2013
        • Hons
    Bar Admissions
    • Solicitor of the Senior Courts of England and Wales
    • Barrister and Solicitor of the High Court of New Zealand
    Accolades
    • Public M&A Team of the Year – British Legal Awards 2024 (Shortlisted)
    • Legal 500 UK, Venture Capital (2022)

    Areas of Expertise

News and Insights

Events